18:50 , Mar 29, 2019 |  BC Week In Review  |  Clinical News

Velicept's overactive bladder therapy meets in Phase IIb

Velicept said solabegron met the primary endpoint in the Phase IIb VEL-2002 trial to treat overactive bladder. The company plans to start a Phase III program of the next-generation adrenergic receptor β 3 (ADRB3) agonist...
17:23 , Mar 19, 2019 |  BC Extra  |  Clinical News

Urovant shares slide on vibegron overactive bladder data

Despite hitting the co-primary endpoints for an indication in need of treatment options, Urovant's overactive bladder therapy vibegron underwhelmed investors with its latest data on Tuesday by performing only marginally better than the generic comparator...
17:06 , Oct 19, 2018 |  BC Week In Review  |  Financial News

Velicept raises additional $15M in series B

Velicept Therapeutics Inc. (Malvern, Pa.) raised $15 million in a series B round extension led by Samsara BioCapital. Existing investors CDK, Fountain Healthcare, Longitude Venture Partners and Becker Ventures also participated. Becker Ventures is Velicept's...
18:16 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Urovant raises $140 million IPO

Urovant Sciences Ltd. (NASDAQ:UROV), the urology subsidiary of Roivant Sciences GmbH (Basel, Switzerland), raised $140 million late Sept. 26 through the sale of 10 million shares at $14 in an IPO underwritten by J.P. Morgan,...
15:34 , Sep 27, 2018 |  BC Extra  |  Financial News

Trio of IPOs price: Arvinas, Sutro, Urovant

Arvinas Inc. (NASDAQ:ARVN), Sutro Biopharma Inc. (NASDAQ:STRO) and Urovant Sciences Ltd. (NASDAQ:UROV) each priced IPOs late Wednesday, raising a total of $345 million. On Thursday, Arvinas gained $0.05 to $16, and Sutro was up $0.20...
17:36 , Sep 21, 2018 |  BC Week In Review  |  Company News

Roivant launches respiratory vant, announces other vant news

Roivant Sciences GmbH (Basel, Switzerland) announced the launch of a new respiratory disease subsidiary, a real-world evidence partnership between its Datavant Inc. (San Francisco, Calif.) subsidiary and CRO Parexel International Corp. (Waltham, Mass.), and its...
21:36 , Sep 17, 2018 |  BC Extra  |  Company News

Roivant launches respiratory vant, announces other vant news

Roivant Sciences GmbH (Basel, Switzerland) had a busy Monday announcing the launch of a new respiratory disease subsidiary, a real-world evidence partnership between its Datavant Inc. (San Francisco, Calif.) subsidiary and CRO Parexel International Corp....
16:56 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Roivant’s urology subsidiary files for $150M IPO

Urovant Sciences Ltd. (London, U.K) proposed on July 13 to raise up to $150 million in an IPO on NASDAQ underwritten by J.P. Morgan, Jefferies and Cowen. The urology play is a wholly owned subsidiary...
23:51 , Jul 13, 2018 |  BC Extra  |  Financial News

Roivant’s urology subsidiary files for $150M IPO

Urovant Sciences Ltd. (London, U.K) proposed Friday to raise up to $150 million in an IPO on NASDAQ underwritten by J.P. Morgan, Jefferies and Cowen. The urology play is a wholly owned subsidiary of Roivant...
22:36 , May 8, 2018 |  BC Extra  |  Preclinical News

SNS nerve loss drives hematopoietic stem cell aging

A paper published in Nature Medicine showed that the loss of sympathetic nervous system (SNS)nerves in bone marrow is a driver of hematopoietic stem cell (HSC) aging, suggesting that agonizing the receptors targeted by SNS-delivered...